The NF-κB Pathway and Cancer Stem Cells

Cells

Volumn 5, Issue 2, 2016, Pages

  Rinkenbaugh, Amanda L ^a,b   Baldwin, Albert S ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cancer; Cancer stem cells; NF B; Self renewal; Tumor initiating cells

Indexed keywords

BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

APOPTOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LIVER CELL CARCINOMA; METASTASIS; NEOPLASM; ONCOGENE RAS; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85117877852     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells5020016     Document Type: Review

References (179)

1. Hayden, M.S.; Ghosh, S. Shared Principles in NF-κB Signaling. Cell 2008, 132, 344-362. [CrossRef] [PubMed]
2. Johnson, C.; Van Antwerp, D.; Hope, T.J. An N-terminal nuclear export signal is required for the nucleocytoplasmic shuttling of IαBα. EMBO J. 1999, 18, 6682-6693. [CrossRef] [PubMed]
3. Huang, T.T.; Kudo, N.; Yoshida, M.; Miyamoto, S. A nuclear export signal in the N-terminal regulatory domain of IαBαcontrols cytoplasmic localization of inactive NF-κB/IαBαcomplexes. Proc. Natl. Acad. Sci. USA 2000, 97, 1014-1019. [CrossRef] [PubMed]
4. Carlotti, F.; Dower, S.K.; Qwarnstrom, E.E. Dynamic Shuttling of Nuclear Factor-κB between the Nucleus and Cytoplasm as a Consequence of Inhibitor Dissociation. J. Biol. Chem. 2000, 275, 41028-41034. [CrossRef] [PubMed]
5. Birbach, A.; Gold, P.; Binder, B.R.; Hofer, E.; De Martin, R.; Schmid, J.A. Signaling Molecules of the NF-κB Pathway Shuttle Constitutively between Cytoplasm and Nucleus. J. Biol. Chem. 2002, 277, 10842-10851. [CrossRef] [PubMed]
6. Ghosh, S.; Hayden, M.S. Celebrating 25 years of NF-κB research. Immunol. Rev. 2012, 246, 5-13. [CrossRef] [PubMed]
7. Bradford, J.W.; Baldwin, A.S. IKK/Nuclear Factor-κB and Oncogenesis. Adv. Cancer Res. 2014, 121, 125-145.[PubMed]
8. Weih, F.; Carrasco, D.; Durham, S.K.; Barton, D.S.; Rizzo, C.A.; Ryseck, R.P.; Lira, S.A.; Bravo, R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κ B/Rel family. Cell 1995, 80, 331-340.[CrossRef]
9. Grossmann, M.; Metcalf, D.; Merryfull, J.; Beg, A.; Baltimore, D.; Gerondakis, S. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc. Natl. Acad. Sci. USA 1999, 96, 11848-11853. [CrossRef] [PubMed]
10. Stein, S.J.; Baldwin, A.S. Deletion of the NF-kappaB subunit p65/RelA in the hematopoietic compartment leads to defects in hematopoietic stem cell function. Blood 2013, 121, 5015-5024. [CrossRef] [PubMed]
11. Zhao, C.; Xiu, Y.; Ashton, J.; Xing, L.; Morita, Y.; Jordan, C.T.; Boyce, B.F. Noncanonical NF-κB Signaling Regulates Hematopoietic Stem Cell Self-Renewal and Microenvironment Interactions. Stem Cells 2012, 30, 709-718. [CrossRef] [PubMed]
12. Zhao, J.L.; Rao, D.S.; O’Connell, R.M.; Garcia-Flores, Y.; Baltimore, D. MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice. Elife 2013, 2, e00537. [CrossRef] [PubMed]
13. Zhao, J.L.; Ma, C.; O’Connell, R.M.; Mehta, A.; DiLoreto, R.; Heath, J.R.; Baltimore, D. Conversion of Danger Signals into Cytokine Signals by Hematopoietic Stem and Progenitor Cells for Regulation of Stress-Induced Hematopoiesis. Cell Stem Cell 2014, 14, 445-459. [CrossRef] [PubMed]
14. Armstrong, L.; Hughes, O.; Yung, S.; Hyslop, L.; Stewart, R.; Wappler, I.; Peters, H.; Walter, T.; Stojkovic, P.; Evans, J. et al. The role of PI3K/AKT, MAPK/ERK and NFκB signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum. Mol. Genet. 2006, 15, 1894-1913. [CrossRef] [PubMed]
15. Deng, P.; Zhou, C.; Alvarez, R.; Hong, C.; Wang, C.-Y. Inhibition of IKK/NF-κB Signaling Enhances Differentiation of Mesenchymal Stromal Cells from Human Embryonic Stem Cells. Stem Cell Rep. 2016. [CrossRef] [PubMed]
16. Lüningschrör, P.; Stöcker, B.; Kaltschmidt, B.; Kaltschmidt, C. miR-290 Cluster Modulates Pluripotency by Repressing Canonical NF-κB Signaling. Stem Cells 2012, 30, 655-664. [CrossRef] [PubMed]
17. Guttridge, D.C.; Albanese, C.; Reuther, J.Y.; Pestell, R.G.; Baldwin, A.S. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 1999, 19, 5785-5799. [CrossRef] [PubMed]
18. Canicio, J.; Ruiz-Lozano, P.; Carrasco, M.; Palacin, M.; Chien, K.; Zorzano, A.; Kaliman, P. Nuclear factor κB-inducing kinase and IκB kinase-α signal skeletal muscle cell differentiation. J. Biol. Chem. 2001, 276, 20228-20233. [CrossRef] [PubMed]
19. Bakkar, N.; Wang, J.; Ladner, K.J.; Wang, H.; Dahlman, J.M.; Carathers, M.; Acharyya, S.; Rudnicki, M.A.; Hollenbach, A.D.; Guttridge, D.C. IKK/NF-κB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J. Cell Biol. 2008, 180, 787-802. [CrossRef] [PubMed]
20. Wilhelmsen, K.C.; Eggleton, K.; Temin, H.M. Nucleic acid sequences of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogene c-rel. J. Virol. 1984, 52, 172-182.[PubMed]
21. Kieran, M.; Blank, V.; Logeat, F.; Vandekerckhove, J.; Lottspeich, F.; Le Bail, O.; Urban, M.B.; Kourilsky, P.; Baeuerle, P.A.; Israel, A. The DNA binding subunit of NF-κB is identical to factor KBF1 and homologous to the rel oncogene product. Cell 1990, 62, 1007-1018.[CrossRef]
22. Finco, T.S.; Westwick, J.K.; Norris, J.L.; Beg, A.A.; Der, C.J.; Baldwin, A.S. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 1997, 272, 24113-24116. [CrossRef] [PubMed]
23. Reuther, J.Y.; Reuther, G.W.; Cortez, D.; Pendergast, A.M.; Baldwin, A.S. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998, 12, 968-981. [CrossRef] [PubMed]
24. Stein, S.J.; Baldwin, A.S. NF-κB suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death. Oncogene 2011, 45, 4557-4566. [CrossRef] [PubMed]
25. Mayo, M.W.; Wang, C.Y.; Cogswell, P.C.; Rogers-Graham, K.S.; Lowe, S.W.; Der, C.J.; Baldwin, A.S. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997, 278, 1812-1815. [CrossRef] [PubMed]
26. Weisz, L.; Damalas, A.; Liontos, M.; Karakaidos, P.; Fontemaggi, G.; Maor-Aloni, R.; Kalis, M.; Levrero, M.; Strano, S.; Gorgoulis, V.G. et al. Mutant p53 Enhances Nuclear Factor-κB Activation by Tumor Necrosis Factor α in Cancer Cells. Cancer Res. 2007, 67, 2396-2401. [CrossRef] [PubMed]
27. Cooks, T.; Pateras, I.S.; Tarcic, O.; Solomon, H.; Schetter, A.J.; Wilder, S.; Lozano, G.; Pikarsky, E.; Forshew, T.; Rozenfeld, N. et al. Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer. Cancer Cell 2013, 23, 634-646. [CrossRef] [PubMed]
28. Di Minin, G.; Bellazzo, A.; Dal Ferro, M.; Chiaruttini, G.; Nuzzo, S.; Bicciato, S.; Piazza, S.; Rami, D.; Bulla, R.; Sommaggio, R. et al. Mutant p53 Reprograms TNF Signaling in Cancer Cells through Interaction with the Tumor Suppressor DAB2IP. Mol. Cell 2014, 56, 617-629. [CrossRef] [PubMed]
29. Qi, H.; Ohh, M. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-κB-dependent antiapoptotic pathway. Cancer Res. 2003, 63, 7076-7080.[PubMed]
30. An, J.; Fisher, M.; Rettig, M.B. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-κB-dependent mechanism. Oncogene 2004, 24, 1563-1570. [CrossRef] [PubMed]
31. An, J.; Rettig, M.B. Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor κB Activity. Mol. Cell. Biol. 2005, 25, 7546-7556. [CrossRef] [PubMed]
32. Gustin, J.A.; Maehama, T.; Dixon, J.E.; Donner, D.B. The PTEN Tumor Suppressor Protein Inhibits Tumor Necrosis Factor-induced Nuclear Factor-κB Activity. J. Biol. Chem. 2001, 276, 27740-27744. [CrossRef] [PubMed]
33. Asano, T.; Yao, Y.; Zhu, J.; Li, D.; Abbruzzese, J.L.; Reddy, S.A.G. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene 2004, 23, 8571-8580. [CrossRef] [PubMed]
34. Ying, H.; Elpek, K.G.; Vinjamoori, A.; Zimmerman, S.M.; Chu, G.C.; Yan, H.; Fletcher-Sananikone, E.; Zhang, H.; Liu, Y.; Wang, W. et al. PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB-Cytokine Network. Cancer Discov. 2011, 1, 158-169. [CrossRef] [PubMed]
35. Wang, X.; Belguise, K.; Kersual, N.; Kirsch, K.H.; Mineva, N.D.; Galtier, F.; Chalbos, D.; Sonenshein, G.E. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat. Cell Biol. 2007, 9, 470-478. [CrossRef] [PubMed]
36. Xu, Y.; Josson, S.; Fang, F.; Oberley, T.D.; St Clair, D.K.; Wan, X.S.; Sun, Y.; Bakthavatchalu, V.; Muthuswamy, A.; St Clair, W.H. RelB Enhances Prostate Cancer Growth: Implications for the Role of the Nuclear Factor-kappaB Alternative Pathway in Tumorigenicity. Cancer Res. 2009, 69, 3267-3271. [CrossRef] [PubMed]
37. Wharry, C.E.; Haines, K.M.; Carroll, R.G.; May, M.J. Constitutive noncanonical NFκB signaling in pancreatic cancer cells. Cancer Biol. Ther. 2014, 8, 1567-1576.[CrossRef]
38. Thu, Y.M.; Su, Y.; Yang, J.; Splittgerber, R.; Na, S.; Boyd, A.; Mosse, C.; Simons, C.; Richmond, A. NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway. Oncogene 2011, 31, 2580-2592. [CrossRef] [PubMed]
39. Lee, D.W.; Ramakrishnan, D.; Valenta, J.; Parney, I.F.; Bayless, K.J.; Sitcheran, R. The NF-κB RelB Protein Is an Oncogenic Driver of Mesenchymal Glioma. PLoS ONE 2013, 8, e57489. [CrossRef] [PubMed]
40. Uno, M.; Saitoh, Y.; Mochida, K.; Tsuruyama, E.; Kiyono, T.; Imoto, I.; Inazawa, J.; Yuasa, Y.; Kubota, T.; Yamaoka, S. NF-κB Inducing Kinase, a Central Signaling Component of the Non-Canonical Pathway of NF-κB, Contributes to Ovarian Cancer Progression. PLoS ONE 2014, 9, e88347. [CrossRef] [PubMed]
41. Li, Y.; Zhou, Q.-L.; Sun, W.; Chandrasekharan, P.; Cheng, H.S.; Ying, Z.; Lakshmanan, M.; Raju, A.; Tenen, D.G.; Cheng, S.-Y. et al. Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat. Cell Biol. 2015, 17, 1327-1338. [CrossRef] [PubMed]
42. Meylan, E.; Dooley, A.L.; Feldser, D.M.; Shen, L.; Turk, E.; Ouyang, C.; Jacks, T. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 461, 104-107. [CrossRef] [PubMed]
43. Bassères, D.S.; Ebbs, A.; Levantini, E.; Baldwin, A.S. Requirement of the NF-κB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 2010, 70, 3537-3546. [CrossRef] [PubMed]
44. Yang, J.; Splittgerber, R.; Yull, F.E.; Kantrow, S.; Ayers, G.D.; Karin, M.; Richmond, A. Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J. Clin. Invest. 2010, 120, 2563-2574. [CrossRef] [PubMed]
45. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. Cell 2011, 144, 646-674. [CrossRef] [PubMed]
46. Baldwin, A.S. Regulation of cell death and autophagy by IKK and NF-κB: Critical mechanisms in immune function and cancer. Immunol. Rev. 2012, 246, 327-345. [CrossRef] [PubMed]
47. Chu, Z.L.; McKinsey, T.A.; Liu, L.; Gentry, J.J.; Malim, M.H.; Ballard, D.W. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc. Natl. Acad. Sci. USA 1997, 94, 10057-10062. [CrossRef] [PubMed]
48. Wang, C.Y.; Mayo, M.W.; Korneluk, R.G.; Goeddel, D.V.; Baldwin, A.S. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281, 1680-1683. [CrossRef] [PubMed]
49. Ramakrishnan, P.; Kahn, D.A.; Baltimore, D. Anti-apoptotic effect of hyperglycemia can allow survival of potentially autoreactive T cells. Cell Death Differ. 2010, 18, 690-699. [CrossRef] [PubMed]
50. Bassères, D.S.; Baldwin, A.S. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25, 6817-6830. [CrossRef] [PubMed]
51. Beroukhim, R.; Mermel, C.H.; Porter, D.; Wei, G.; Raychaudhuri, S.; Donovan, J.; Barretina, J.; Boehm, J.S.; Dobson, J.; Urashima, M. et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463, 899-905. [CrossRef] [PubMed]
52. Boehm, J.S.; Zhao, J.J.; Yao, J.; Kim, S.Y.; Firestein, R.; Dunn, I.F.; Sjostrom, S.K.; Garraway, L.A.; Weremowicz, S.; Richardson, A.L. et al. Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene. Cell 2007, 129, 1065-1079. [CrossRef] [PubMed]
53. Orlowski, R.Z.; Baldwin, A.S. NF-κB as a therapeutic target in cancer. Trends Mol. Med. 2002, 8, 385-389.[CrossRef]
54. Neri, A.; Chang, C.C.; Lombardi, L.; Salina, M.; Corradini, P.; Maiolo, A.T.; Chaganti, R.S.; Dalla-Favera, R. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell 1991, 67, 1075-1087.[CrossRef]
55. Parker, M.; Mohankumar, K.M.; Punchihewa, C.; Weinlich, R.; Dalton, J.D.; Li, Y.; Lee, R.; Tatevossian, R.G.; Phoenix, T.N.; Thiruvenkatam, R. et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 2014, 506, 451-455. [CrossRef] [PubMed]
56. Bredel, M.; Scholtens, D.M.; Yadav, A.K.; Alvarez, A.A.; Renfrow, J.J.; Chandler, J.P.; Yu, I.L.Y.; Carro, M.S.; Dai, F.; Tagge, M.J. et al. NFKBIA Deletion in Glioblastomas. N. Engl. J. Med. 2011, 364, 627-637. [CrossRef] [PubMed]
57. Lim, K.-H.; Yang, Y.; Staudt, L.M. Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol. Rev. 2012, 246, 359-378. [CrossRef] [PubMed]
58. Merkhofer, E.C.; Cogswell, P.; Baldwin, A.S. Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKα. Oncogene 2010, 29, 1238-1248. [CrossRef] [PubMed]
59. Tanaka, K.; Babic, I.; Nathanson, D.; Akhavan, D.; Guo, D.; Gini, B.; Dang, J.; Zhu, S.; Yang, H.; De Jesus, J. et al. Oncogenic EGFR Signaling Activates an mTORC2-NF-κB Pathway That Promotes Chemotherapy Resistance. Cancer Discov. 2011, 1, 524-538. [CrossRef] [PubMed]
60. Dan, H.C.; Adli, M.; Baldwin, A.S. Regulation of Mammalian Target of Rapamycin Activity in PTEN-Inactive Prostate Cancer Cells by IκB Kinase α. Cancer Res. 2007, 67, 6263-6269. [CrossRef] [PubMed]
61. Dan, H.C.; Cooper, M.J.; Cogswell, P.C.; Duncan, J.A.; Ting, J.P.Y.; Baldwin, A.S. Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKK. Genes Dev. 2008, 22, 1490-1500. [CrossRef] [PubMed]
62. Xu, Y.; Lai, E.; Liu, J.; Lin, J.; Yang, C.; Jia, C.; Li, Y.; Bai, X.; Li, M. IKK interacts with rictor and regulates mTORC2. Cell. Signal. 2013, 25, 2239-2245. [CrossRef] [PubMed]
63. Dan, H.C.; Ebbs, A.; Pasparakis, M.; Van Dyke, T.; Bassères, D.S.; Baldwin, A.S. Akt-dependent Activation of mTORC1 Complex Involves Phosphorylation of mTOR (Mammalian Target of Rapamycin) by IκB Kinase α (IKKα). J. Biol. Chem. 2014, 289, 25227-25240. [CrossRef] [PubMed]
64. Zhang, W.; Tan, W.; Wu, X.; Poustovoitov, M.; Strasner, A.; Li, W.; Borcherding, N.; Ghassemian, M.; Karin, M. A NIK-IKKα Module Expands ErbB2-Induced Tumor-Initiating Cells by Stimulating Nuclear Export of p27/Kip1. Cancer Cell 2013, 23, 647-659. [CrossRef] [PubMed]
65. Xia, Y.; Padre, R.C.; De Mendoza, T.H.; Bottero, V.; Tergaonkar, V.B.; Verma, I.M. Phosphorylation of p53 by IκB kinase 2 promotes its degradation by beta-TrCP. Proc. Natl. Acad. Sci. USA 2009, 106, 2629-2634. [CrossRef] [PubMed]
66. Greten, F.R.; Eckmann, L.; Greten, T.F.; Park, J.M.; Li, Z.-W.; Egan, L.J.; Kagnoff, M.F.; Karin, M. IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer. Cell 2004, 118, 285-296. [CrossRef] [PubMed]
67. Maeda, S.; Kamata, H.; Luo, J.-L.; Leffert, H.; Karin, M. IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis. Cell 2005, 121, 977-990. [CrossRef] [PubMed]
68. Sakurai, T.; Maeda, S.; Chang, L.; Karin, M. Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. USA 2006, 103, 10544-10551. [CrossRef] [PubMed]
69. DiDonato, J.A.; Mercurio, F.; Karin, M. NF-κB and the link between inflammation and cancer. Immunol. Rev. 2012, 246, 379-400. [CrossRef] [PubMed]
70. Erez, N.; Truitt, M.; Olson, P.; Hanahan, D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner. Cancer Cell 2010, 17, 135-147. [CrossRef] [PubMed]
71. Koliaraki, V.; Pasparakis, M.; Kollias, G. IKKbeta in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J. Exp. Med. 2015, 205, 331.
72. Pallangyo, C.K.; Ziegler, P.K.; Greten, F.R. IKKbeta acts as a tumor suppressor in cancer-associated fibroblasts during intestinal tumorigenesis. J. Exp. Med. 2015, 223, 162.
73. Saccani, A.; Schioppa, T.; Porta, C.; Biswas, S.K.; Nebuloni, M.; Vago, L.; Bottazzi, B.; Colombo, M.P.; Mantovani, A.; Sica, A. p50 Nuclear Factor-κB Overexpression in Tumor-Associated Macrophages Inhibits M1 Inflammatory Responses and Antitumor Resistance. Cancer Res. 2006, 66, 11432-11440. [CrossRef] [PubMed]
74. Hagemann, T.; Lawrence, T.; McNeish, I.; Charles, K.A.; Kulbe, H.; Thompson, R.G.; Robinson, S.C.; Balkwill, F.R. “Re-educating” tumor-associated macrophages by targeting NF-κB. J. Exp. Med. 2008, 205, 1261-1268. [CrossRef] [PubMed]
75. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737. [CrossRef] [PubMed]
76. Singh, S.K.; Clarke, I.D.; Terasaki, M.; Bonn, V.E.; Hawkins, C.; Squire, J.; Dirks, P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63, 5821-5828.[PubMed]
77. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature 2004, 432, 396-401. [CrossRef] [PubMed]
78. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988. [CrossRef] [PubMed]
79. Collins, A.T. Prospective Identification of Tumorigenic Prostate Cancer Stem Cells. Cancer Res. 2005, 65, 10946-10951. [CrossRef] [PubMed]
80. Ricci-Vitiani, L.; Lombardi, D.G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells. Nature 2006, 445, 111-115. [CrossRef] [PubMed]
81. Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F.; Simeone, D.M. Identification of Pancreatic Cancer Stem Cells. Cancer Res. 2007, 67, 1030-1037. [CrossRef] [PubMed]
82. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111. [CrossRef] [PubMed]
83. Chen, R.; Nishimura, M.C.; Bumbaca, S.M.; Kharbanda, S.; Forrest, W.F.; Kasman, I.M.; Greve, J.M.; Soriano, R.H.; Gilmour, L.L.; Rivers, C.S. et al. A Hierarchy of Self-Renewing Tumor-Initiating Cell Types in Glioblastoma. Cancer Cell 2010, 17, 362-375. [CrossRef] [PubMed]
84. Bruce, W.R.; van der Gaag, H. A Quantitative Assay for the Number of Murine Lymphoma Cells Capable of Proliferation in vivo. Nature 1963, 199, 79-80. [CrossRef] [PubMed]
85. Reynolds, B.A.; Weiss, S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992, 255, 1707-1710. [CrossRef] [PubMed]
86. Hemmati, H.D.; Nakano, I.; Lazareff, J.A.; Masterman-Smith, M.; Geschwind, D.H.; Bronner-Fraser, M.; Kornblum, H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 2003, 100, 15178-15183. [CrossRef] [PubMed]
87. Nguyen, L.V.; Vanner, R.; Dirks, P.; Eaves, C.J. Cancer stem cells: An evolving concept. Nat. Rev. Cancer 2012, 12, 133-143. [CrossRef] [PubMed]
88. Dalerba, P.; Dylla, S.J.; Park, I.-K.; Liu, R.; Wang, X.; Cho, R.W.; Hoey, T.; Gurney, A.; Huang, E.H.; Simeone, D.M. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104, 10158-10163. [CrossRef] [PubMed]
89. Sales, K.M.; Winslet, M.C.; Seifalian, A.M. Stem Cells and Cancer: An Overview. Stem Cell Rev. 2007, 3, 249-255. [CrossRef] [PubMed]
90. Guzman, M.L.; Neering, S.J.; Upchurch, D.; Grimes, B.; Howard, D.S.; Rizzieri, D.A.; Luger, S.M.; Jordan, C.T. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98, 2301-2307. [CrossRef] [PubMed]
91. Rajasekhar, V.K.; Studer, L.; Gerald, W.; Socci, N.D.; Scher, H.I. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nat. Commun. 2011, 2, 162. [CrossRef] [PubMed]
92. Garner, J.M.; Fan, M.; Yang, C.H.; Du, Z.; Sims, M.; Davidoff, A.M.; Pfeffer, L.M. Constitutive Activation of Signal Transducer and Activator of Transcription 3 (STAT3) and Nuclear Factor-κB Signaling in Glioblastoma Cancer Stem Cells Regulates the Notch Pathway. J. Biol. Chem. 2013, 288, 26167-26176. [CrossRef] [PubMed]
93. Song, L.; Liu, L.; Wu, Z.; Li, Y.; Ying, Z.; Lin, C.; Wu, J.; Hu, B.; Cheng, S.-Y.; Li, M.; Li, J. TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets. J. Clin. Invest. 2012, 122, 3563-3578. [CrossRef] [PubMed]
94. Tafani, M.; Di Vito, M.; Frati, A.; Pellegrini, L.; De Santis, E.; Sette, G.; Eramo, A.; Sale, P.; Mari, E.; Santoro, A. et al. Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J. Neuroinflamm. 2011, 8, 32. [CrossRef] [PubMed]
95. Murohashi, M.; Hinohara, K.; Kuroda, M.; Isagawa, T.; Tsuji, S.; Kobayashi, S.; Umezawa, K.; Tojo, A.; Aburatani, H.; Gotoh, N. Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. Br. J. Cancer 2009, 102, 206-212. [CrossRef] [PubMed]
96. Liu, R.; Wang, X.; Chen, G.Y.; Dalerba, P.; Gurney, A.; Hoey, T.; Sherlock, G.; Lewicki, J.; Shedden, K.; Clarke, M.F. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 2007, 356, 217-226. [CrossRef] [PubMed]
97. Birnie, R.; Bryce, S.D.; Roome, C.; Dussupt, V.; Droop, A.; Lang, S.H.; Berry, P.A.; Hyde, C.F.; Lewis, J.L.; Stower, M.J. et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol. 2008, 9, R83. [CrossRef] [PubMed]
98. Leizer, A.L.; Alvero, A.B.; Fu, H.H.; Holmberg, J.C.; Cheng, Y.-C.; Silasi, D.-A.; Rutherford, T.; Mor, G. Regulation of Inflammation by the NF-κB Pathway in Ovarian Cancer Stem Cells. Am. J. Reprod. Immunol. 2010, 65, 438-447. [CrossRef] [PubMed]
99. Korkaya, H.; Liu, S.; Wicha, M.S. Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer’s Inflammatory Roots. Clin. Can. Res. 2011, 17, 6125-6129. [CrossRef] [PubMed]
100. Pratt, M.A.C.; Tibbo, E.; Robertson, S.J.; Jansson, D.; Hurst, K.; Perez-Iratxeta, C.; Lau, R.; Niu, M.Y. The canonical NF-κB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene 2009, 28, 2710-2722. [CrossRef] [PubMed]
101. Liu, M.; Sakamaki, T.; Casimiro, M.C.; Willmarth, N.E.; Quong, A.A.; Ju, X.; Ojeifo, J.; Jiao, X.; Yeow, W.-S.; Katiyar, S. et al. The canonical NF-κB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 2010, 70, 10464-10473. [CrossRef] [PubMed]
102. Cao, Y.; Luo, J.-L.; Karin, M. IκB kinase α kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc. Natl. Acad. Sci. USA 2007, 104, 15852-15857. [CrossRef] [PubMed]
103. Myant, K.B.; Cammareri, P.; McGhee, E.J.; Ridgway, R.A.; Huels, D.J.; Cordero, J.B.; Schwitalla, S.; Kalna, G.; Ogg, E.-L.; Athineos, D. et al. ROS Production and NF-κB Activation Triggered by RAC1 Facilitate WNT-Driven Intestinal Stem Cell Proliferation and Colorectal Cancer Initiation. Cell Stem Cell 2013, 12, 761-773. [CrossRef] [PubMed]
104. Chefetz, I.; Alvero, A.; Holmberg, J.; Lebowitz, N.; Craveiro, V.; Yang-Hartwich, Y.; Yin, G.; Squillace, L.; Gurrea Soteras, M.; Aldo, P. et al. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle 2014, 12, 511-521. [CrossRef] [PubMed]
105. Moreira, D.; Zhang, Q.; Hossain, D.M.S.; Nechaev, S.; Li, H.; Kowolik, C.M.; D’Apuzzo, M.; Forman, S.; Jones, J.; Pal, S.K. et al. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells. Oncotarget 2015, 6, 17302-17313. [CrossRef] [PubMed]
106. Gallipoli, P.; Pellicano, F.; Morrison, H.; Laidlaw, K.; Allan, E.K.; Bhatia, R.; Copland, M.; Jørgensen, H.G.; Holyoake, T.L. Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood 2013, 122, 3335-3339. [CrossRef] [PubMed]
107. Kagoya, Y.; Yoshimi, A.; Kataoka, K.; Nakagawa, M.; Kumano, K.; Arai, S.; Kobayashi, H.; Saito, T.; Iwakura, Y.; Kurokawa, M. Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. J. Clin. Invest. 2014, 124, 528-542. [CrossRef] [PubMed]
108. Storci, G.; Sansone, P.; Mari, S.; D’Uva, G.; Tavolari, S.; Guarnieri, T.; Taffurelli, M.; Ceccarelli, C.; Santini, D.; Chieco, P. et al. TNFα up-regulates SLUG via the NF-κB/HIF1α axis, which imparts breast cancer cells with a stem cell-like phenotype. J. Cell. Physiol. 2010, 225, 682-691. [CrossRef] [PubMed]
109. Wang, D.; Fu, L.; Sun, H.; Guo, L.; DuBois, R.N. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology 2015, 149, 1884-1895. [CrossRef] [PubMed]
110. Parajuli, P.; Anand, R.; Mandalaparty, C.; Suryadevara, R.; Sriranga, P.U.; Michelhaugh, S.K.; Cazacu, S.; Finniss, S.; Thakur, A.; Lum, L.G. et al. Preferential expression of functional IL-17R in glioma stem cells: Potential role in self-renewal. Oncotarget 2016, 7, 6121-6135.[PubMed]
111. Iliopoulos, D.; Hirsch, H.A.; Struhl, K. An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139, 693-706. [CrossRef] [PubMed]
112. Iliopoulos, D.; Hirsch, H.A.; Wang, G.; Struhl, K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 2011, 108, 1397-1402. [CrossRef] [PubMed]
113. Xu, C.; Sun, X.; Qin, S.; Wang, H.; Zheng, Z.; Xu, S.; Luo, G.; Liu, P.; Liu, J.; Du, N. et al. Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cells. Cell Cycle 2015, 14, 1686-1697. [CrossRef] [PubMed]
114. Reynaud, D.; Pietras, E.; Barry-Holson, K.; Mir, A.; Binnewies, M.; Jeanne, M.; Sala-Torra, O.; Radich, J.P.; Passegué, E. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011, 20, 661-673. [CrossRef] [PubMed]
115. Wang, H.; Lathia, J.D.; Wu, Q.; Wang, J.; Li, Z.; Heddleston, J.M.; Eyler, C.E.; Elderbroom, J.; Gallagher, J. et al. Targeting Interleukin 6 Signaling Suppresses Glioma Stem Cell Survival and Tumor Growth. Stem Cells 2009, 27, 2393-2404. [CrossRef] [PubMed]
116. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T.L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.; Finklestein, D.; Allen, M. et al. A Perivascular Niche for Brain Tumor Stem Cells. Cancer Cell 2007, 11, 69-82. [CrossRef] [PubMed]
117. Charles, N.; Ozawa, T.; Squatrito, M.; Bleau, A.-M.; Brennan, C.W.; Hambardzumyan, D.; Holland, E.C. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010, 6, 141-152. [CrossRef] [PubMed]
118. Xiang, T.; Long, H.; He, L.; Han, X.; Lin, K.; Liang, Z.; Zhuo, W.; Xie, R.; Zhu, B. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer. Oncogene 2013, 34, 165-176. [CrossRef] [PubMed]
119. Alvero, A.B.; Fu, H.H.; Holmberg, J.; Visintin, I.; Mor, L.; Marquina, C.C.; Oidtman, J.; Silasi, D.-A.; Mor, G. Stem-Like Ovarian Cancer Cells Can Serve as Tumor Vascular Progenitors. Stem Cells 2009, 27, 2405-2413. [CrossRef] [PubMed]
120. Wang, R.; Chadalavada, K.; Wilshire, J.; Kowalik, U.; Hovinga, K.E.; Geber, A.; Fligelman, B.; Leversha, M.; Brennan, C.; Tabar, V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468, 829-833. [CrossRef] [PubMed]
121. Soda, Y.; Marumoto, T.; Friedmann-Morvinski, D.; Soda, M.; Liu, F.; Michiue, H.; Pastorino, S.; Yang, M.; Hoffman, R.M.; Kesari, S.; Verma, I.M. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. USA 2011, 108, 4274-4280. [CrossRef] [PubMed]
122. Cao, L.; Fan, X.; Jing, W.; Liang, Y.; Chen, R.; Liu, Y.; Zhu, M.; Jia, R.; Wang, H.; Zhang, X. et al. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway. Oncotarget 2015, 6, 6627-6640. [CrossRef] [PubMed]
123. Malanchi, I.; Santamaria-Martínez, A.; Susanto, E.; Peng, H.; Lehr, H.-A.; Delaloye, J.-F.; Huelsken, J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2011, 481, 85-89. [CrossRef] [PubMed]
124. Lambert, A.W.; Wong, C.K.; Ozturk, S.; Papageorgis, P.; Raghunathan, R.; Alekseyev, Y.; Gower, A.C.; Reinhard, B.M.; Abdolmaleky, H.M.; Thiagalingam, S. Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells. Mol. Cancer Res. 2016, 14, 103-113. [CrossRef] [PubMed]
125. Schramek, D.; Leibbrandt, A.; Sigl, V.; Kenner, L.; Pospisilik, J.A.; Lee, H.J.; Hanada, R.; Joshi, P.A.; Aliprantis, A.; Glimcher, L. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468, 98-102. [CrossRef] [PubMed]
126. Mani, S.A.; Guo, W.; Liao, M.-J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M. et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. Cell 2008, 133, 704-715. [CrossRef] [PubMed]
127. Barberà, M.J.; Puig, I.; Domínguez, D.; Julien-Grille, S.; Guaita-Esteruelas, S.; Peiró, S.; Baulida, J.; Francí, C.; Dedhar, S.; Larue, L. et al. Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene 2004, 23, 7345-7354. [CrossRef] [PubMed]
128. Kim, H.J.; Litzenburger, B.C.; Cui, X.; Delgado, D.A.; Grabiner, B.C.; Lin, X.; Lewis, M.T.; Gottardis, M.M.; Wong, T.W.; Attar, R.M. et al. Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-κB and Snail. Mol. Cell. Biol. 2007, 27, 3165-3175. [CrossRef] [PubMed]
129. Belguise, K.; Guo, S.; Yang, S.; Rogers, A.E.; Seldin, D.C.; Sherr, D.H.; Sonenshein, G.E. Green Tea Polyphenols Reverse Cooperation between c-Rel and CK2 that Induces the Aryl Hydrocarbon Receptor, Slug, and an Invasive Phenotype. Cancer Res. 2007, 67, 11742-11750. [CrossRef] [PubMed]
130. Kumar, M.; Allison, D.F.; Baranova, N.N.; Wamsley, J.J.; Katz, A.J.; Bekiranov, S.; Jones, D.R.; Mayo, M.W. NF-κB Regulates Mesenchymal Transition for the Induction of Non-Small Cell Lung Cancer Initiating Cells. PLoS ONE 2013, 8, e68597. [CrossRef] [PubMed]
131. Chua, H.L.; Bhat-Nakshatri, P.; Clare, S.E.; Morimiya, A.; Badve, S.; Nakshatri, H. NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: Potential involvement of ZEB-1 and ZEB-2. Oncogene 2006, 26, 711-724. [CrossRef] [PubMed]
132. Wang, S.M.; Coljee, V.W.; Pignolo, R.J.; Rotenberg, M.O.; Cristofalo, V.J.; Sierra, F. Cloning of the human twist gene: Its expression is retained in adult mesodermally-derived tissues. Gene 1997, 187, 83-92.[CrossRef]
133. Kanegae, Y.; Tavares, A.T.; Izpisúa Belmonte, J.C.; Verma, I.M. Role of Rel/NF-κB transcription factors during the outgrowth of the vertebrate limb. Nature 1998, 392, 611-614.[PubMed]
134. Takeda, K.; Takeuchi, O.; Tsujimura, T.; Itami, S.; Adachi, O.; Kawai, T.; Sanjo, H.; Yoshikawa, K.; Terada, N.; Akira, S. Limb and skin abnormalities in mice lacking IKKα. Science 1999, 284, 313-316. [CrossRef] [PubMed]
135. Šošić, D.; Richardson, J.A.; Yu, K.; Ornitz, D.M.; Olson, E.N. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-κB activity. Cell 2003, 112, 169-180.[CrossRef]
136. Pham, C.G.; Bubici, C.; Zazzeroni, F.; Knabb, J.R.; Papa, S.; Kuntzen, C.; Franzoso, G. Upregulation of Twist-1 by NF-κB Blocks Cytotoxicity Induced by Chemotherapeutic Drugs. Mol. Cell. Biol. 2007, 27, 3920-3935. [CrossRef] [PubMed]
137. Min, C.; Eddy, S.F.; Sherr, D.H.; Sonenshein, G.E. NF-κB and epithelial to mesenchymal transition of cancer. J. Cell. Biochem. 2008, 104, 733-744. [CrossRef] [PubMed]
138. Wu, Y.; Deng, J.; Rychahou, P.G.; Qiu, S.; Evers, B.M.; Zhou, B.P. Stabilization of Snail by NF-κB Is Required for Inflammation-Induced Cell Migration and Invasion. Cancer Cell 2009, 15, 416-428. [CrossRef] [PubMed]
139. Li, C.W.; Xia, W.; Huo, L.; Lim, S.O.; Wu, Y.; Hsu, J.L.; Chao, C.H.; Yamaguchi, H.; Yang, N.K.; Ding, Q. et al. Epithelial-Mesenchymal Transition Induced by TNF-α Requires NF-κB-Mediated Transcriptional Upregulation of Twist1. Cancer Res. 2012, 72, 1290-1300. [CrossRef] [PubMed]
140. Huber, M.A.; Azoitei, N.; Baumann, B.; Grünert, S.; Sommer, A.; Pehamberger, H.; Kraut, N.; Beug, H.; Wirth, T. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 2004, 114, 569-581. [CrossRef] [PubMed]
141. Palafox, M.; Ferrer, I.; Pellegrini, P.; Vila, S.; Hernandez-Ortega, S.; Urruticoechea, A.; Climent, F.; Soler, M.T.; Munoz, P.; Vinals, F. et al. RANK Induces Epithelial-Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis. Cancer Res. 2012, 72, 2879-2888. [CrossRef] [PubMed]
142. Asiedu, M.K.; Beauchamp-Perez, F.D.; Ingle, J.N.; Behrens, M.D.; Radisky, D.C.; Knutson, K.L. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 2013, 33, 1316-1324. [CrossRef] [PubMed]
143. Wamsley, J.J.; Kumar, M.; Allison, D.F.; Clift, S.H.; Holzknecht, C.M.; Szymura, S.J.; Hoang, S.A.; Xu, X.; Moskaluk, C.A.; Jones, D.R. et al. Activin Upregulation by NF-κB Is Required to Maintain Mesenchymal Features of Cancer Stem-like Cells in Non-Small Cell Lung Cancer. Cancer Res. 2015, 75, 426-435. [CrossRef] [PubMed]
144. Es-haghi, M.; Soltanian, S.; Dehghani, H. Perspective: Cooperation of Nanog, NF-κB, and CXCR4 in a regulatory network for directed migration of cancer stem cells. Tumor Biol. 2015. [CrossRef] [PubMed]
145. Singh, A.P.; Arora, S.; Bhardwaj, A.; Srivastava, S.K.; Kadakia, M.P.; Wang, B.; Grizzle, W.E.; Owen, L.B.; Singh, S. CXCL12/CXCR4 Protein Signaling Axis Induces Sonic Hedgehog Expression in Pancreatic Cancer Cells via Extracellular Regulated Kinase-and Akt Kinase-mediated Activation of Nuclear Factor-κB: Implications for Bidirectional Tumor-Stromal Interactions. J. Biol. Chem. 2012, 287, 39115-39124. [CrossRef] [PubMed]
146. Helbig, G.; Christopherson, K.W.; Bhat-Nakshatri, P.; Kumar, S.; Kishimoto, H.; Miller, K.D.; Broxmeyer, H.E.; Nakshatri, H. NF-κB Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4. J. Biol. Chem. 2003, 278, 21631-21638. [CrossRef] [PubMed]
147. Zhi, Y.; Duan, Y.; Zhou, X.; Yin, X.; Guan, G.; Zhang, H.; Dong, Q.; Yang, K. NF-κB signaling pathway confers neuroblastoma cells migration and invasion ability via the regulation of CXCR4. Med. Sci. Monit. 2014, 20, 2746-2752.[PubMed]
148. Himelstein, B.P.; Lee, E.J.; Sato, H.; Seiki, M.; Muschel, R.J. Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line. Oncogene 1997, 14, 1995-1998. [CrossRef] [PubMed]
149. Farina, A.R.; Tacconelli, A.; Vacca, A.; Maroder, M.; Gulino, A.; Mackay, A.R. Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor κB elements. Cell Growth Differ. 1999, 10, 353-367.[PubMed]
150. Ricca, A.; Biroccio, A.; Del Bufalo, D.; Mackay, A.R.; Santoni, A.; Cippitelli, M. BCL-2 over-expression enhances NF-κB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int. J. Cancer 2000, 86, 188-196.[CrossRef]
151. Han, Y.P.; Tuan, T.L.; Wu, H.; Hughes, M.; Garner, W.L. TNF-α stimulates activation of pro-MMP2 in human skin through NF-κB mediated induction of MT1-MMP. J. Cell. Sci. 2001, 114, 131-139.[PubMed]
152. Philip, S.; Bulbule, A.; Kundu, G.C. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κB-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. 2001, 276, 44926-44935. [CrossRef] [PubMed]
153. Connelly, L.; Robinson-Benion, C.; Chont, M.; Saint-Jean, L.; Li, H.; Polosukhin, V.V.; Blackwell, T.S.; Yull, F.E. A transgenic model reveals important roles for the NF-κB alternative pathway (p100/p52) in mammary development and links to tumorigenesis. J. Biol. Chem. 2007, 282, 10028-10035. [CrossRef] [PubMed]
154. Long, H.; Xie, R.; Xiang, T.; Zhao, Z.; Lin, S.; Liang, Z.; Chen, Z.; Zhu, B. Autocrine CCL5 Signaling Promotes Invasion and Migration of CD133+ Ovarian Cancer Stem-Like Cells via NF-κB-Mediated MMP-9 Upregulation. Stem Cells 2012, 30, 2309-2319. [CrossRef] [PubMed]
155. Huang, S.; Robinson, J.B.; Deguzman, A.; Bucana, C.D.; Fidler, I.J. Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000, 60, 5334-5339.[PubMed]
156. Yamamoto, M.; Taguchi, Y.; Ito-Kureha, T.; Semba, K.; Yamaguchi, N.; Inoue, J.-I. NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat. Commun. 2013, 4, 2299. [CrossRef] [PubMed]
157. Ohtsu, N.; Nakatani, Y.; Yamashita, D.; Ohue, S.; Ohnishi, T.; Kondo, T. Eva1 Maintains the Stem-like Character of Glioblastoma-Initiating Cells by Activating the Noncanonical NF-κB Signaling Pathway. Cancer Res. 2016, 76, 171-181. [CrossRef] [PubMed]
158. Guzman, M.L.; Swiderski, C.F.; Howard, D.S.; Grimes, B.A.; Rossi, R.M.; Szilvassy, S.J.; Jordan, C.T. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. USA 2002, 99, 16220-16225. [CrossRef] [PubMed]
159. Guzman, M.L.; Rossi, R.M.; Karnischky, L.; Li, X.; Peterson, D.R.; Howard, D.S.; Jordan, C.T. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005, 105, 4163-4169. [CrossRef] [PubMed]
160. Hassane, D.C.; Guzman, M.L.; Corbett, C.; Li, X.; Abboud, R.; Young, F.; Liesveld, J.L.; Carroll, M.; Jordan, C.T. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008, 111, 5654-5662. [CrossRef] [PubMed]
161. Zhou, J.; Zhang, H.; Gu, P.; Bai, J.; Margolick, J.B.; Zhang, Y. NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 2007, 111, 419-427. [CrossRef] [PubMed]
162. Zhang, L.; Ren, X.; Cheng, Y.; Liu, X.; Allen, J.E.; Zhang, Y.; Yuan, Y.; Huang, S.-Y.; Yang, W.; Berg, A. et al. The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biol. Ther. 2014, 15, 602-611. [CrossRef] [PubMed]
163. Nogueira, L.; Ruiz-Ontañon, P.; Vazquez-Barquero, A.; Lafarga, M.; Berciano, M.T.; Aldaz, B.; Grande, L.; Casafont, I.; Segura, V.; Robles, E.F. et al. Blockade of the NFκB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo. Oncogene 2011, 30, 3537-3548. [CrossRef] [PubMed]
164. Jazirehi, A.R.; Huerta-Yepez, S.; Cheng, G.; Bonavida, B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin’s lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 2005, 65, 264-276.[PubMed]
165. Akinleye, A.; Chen, Y.; Mukhi, N.; Song, Y.; Liu, D. Ibrutinib and novel BTK inhibitors in clinical development. J. Hematol. Oncol. 2013, 6, 59. [CrossRef] [PubMed]
166. Xue, W.; Meylan, E.; Oliver, T.G.; Feldser, D.M.; Winslow, M.M.; Bronson, R.; Jacks, T. Response and Resistance to NF-κB Inhibitors in Mouse Models of Lung Adenocarcinoma. Cancer Discov. 2011, 1, 236-247. [CrossRef] [PubMed]
167. Bassères, D.S.; Ebbs, A.; Cogswell, P.C.; Baldwin, A.S. IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity. Genes Cancer 2014, 5, 41-55.[PubMed]
168. Friedmann-Morvinski, D.; Narasimamurthy, R.; Xia, Y.; Myskiw, C.; Soda, Y.; Verma, I.M. Targeting NF-κB in glioblastoma: A therapeutic approach. Science Advances 2016, 2, e1501292-e1501292. [CrossRef] [PubMed]
169. Habineza Ndikuyeze, G.; Gaurnier-Hausser, A.; Patel, R.; Baldwin, A.S.; May, M.J.; Flood, P.; Krick, E.; Propert, K.J.; Mason, N.J. A Phase I Clinical Trial of Systemically Delivered NEMO Binding Domain Peptide in Dogs with Spontaneous Activated B-Cell like Diffuse Large B-Cell Lymphoma. PLoS ONE 2014, 9, e95404.
170. Gaurnier-Hausser, A.; Patel, R.; Baldwin, A.S.; May, M.J.; Mason, N.J. NEMO-Binding Domain Peptide Inhibits Constitutive NF-κB Activity and Reduces Tumor Burden in a Canine Model of Relapsed, Refractory Diffuse Large B-Cell Lymphoma. Clin. Can. Res. 2011, 17, 4661-4671. [CrossRef] [PubMed]
171. Wang, C.Y.; Mayo, M.W.; Baldwin, A.S. TNF-and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 1996, 274, 784-787. [CrossRef] [PubMed]
172. Wang, C.Y.; Cusack, J.C.; Liu, R.; Baldwin, A.S. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med. 1999, 5, 412-417. [CrossRef] [PubMed]
173. Cusack, J.C.; Liu, R.; Houston, M.; Abendroth, K.; Elliott, P.J.; Adams, J.; Baldwin, A.S. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition. Cancer Res. 2001, 61, 3535-3540. [PubMed]
174. Fukushima, T.; Kawaguchi, M.; Yorita, K.; Tanaka, H.; Takeshima, H.; Umezawa, K.; Kataoka, H. Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma. Neuro-Oncology 2011, 14, 19-28. [CrossRef] [PubMed]
175. Brassesco, M.S.; Roberto, G.M.; Morales, A.G.; Oliveira, J.C.; Delsin, L.E.A.; Pezuk, J.A.; Valera, E.T.; Carlotti, C.G.; Rego, E.M.; de Oliveira, H.F. et al. Inhibition of NF-κB by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and-Radiation Cytotoxicity in Glioblastoma Cells. Chemother. Res. Pract. 2013, 2013, 1-16. [CrossRef] [PubMed]
176. Shukla, S.; Pia Patric, I.R.; Thinagararjan, S.; Srinivasan, S.; Mondal, B.; Hegde, A.S.; Chandramouli, B.A.; Santosh, V.; Arivazhagan, A.; Somasundaram, K. The NPTX2-PTEN-NFκB nexus is an essential component of a prognostic DNA methylation signature of glioblastoma. Cancer Res. 2013, 73, 6563-6573. [CrossRef] [PubMed]
177. Xi, G.; Hayes, E.; Lewis, R.; Ichi, S.; Mania-Farnell, B.; Shim, K.; Takao, T.; Allender, E.; Mayanil, C.S.; Tomita, T. CD133 and DNA-PK regulate MDR1 via the PI3K-or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro. Oncogene 2015, 35, 241-250. [CrossRef] [PubMed]
178. Seguin, L.; Kato, S.; Franovic, A.; Camargo, M.F.; Lesperance, J.; Elliott, K.C.; Yebra, M.; Mielgo, A.; Lowy, A.M.; Husain, H. et al. An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol. 2014, 16, 457-468. [CrossRef] [PubMed]
179. Wee, Z.N.; Yatim, S.M.J.M.; Kohlbauer, V.K.; Feng, M.; Goh, J.Y.; Yi, B.; Lee, P.L.; Zhang, S.; Wang, P.P.; Lim, E. et al. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat. Commun. 2015, 6, 8746. [CrossRef] [PubMed]